Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company, signed a license agreement with Italfarmaco S.p.A. (ITF), a specialty pharmaceutical company, to develop and commercialize a novel peptide-drug conjugate (PDC). Under the terms of the agreement, ITF will use NMS’s linker-payload technology to develop a novel PDC product candidate. NMS has implemented linker-payload GMP manufacturing and supply at a CDMO referred by NMS. ITF will be responsible for generating the t...